Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

16.62 +0.02 (+0.15%)
Streaming Delayed Price Updated: 10:31 AM EDT, May 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Teva Pharmaceutical Industries ADR

< Previous 1 2 3 4 5 6 7 Next >
Direct Relief, the National Association of Free and Charitable Clinics and Teva Pharmaceuticals Partner to Advance Access to Behavioral Health Services
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reaches Agreement With West Virginia to Settle the State’s Opioid-Related Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Help Inform Treatment Decisions at American Thoracic Society 2022 Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Publishes 2021 ESG Progress Report, Showcasing Further Integration of ESG Into Business, Robust Targets and Strengthened ESG Governance Structure
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reports First Quarter 2022 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent Dispute
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Host Conference Call to Discuss First Quarter 2022 Financial Results at 8 a.m. ET on May 3, 2022
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets at 2022 American Academy of Neurology Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reaches Agreement With Florida to Settle the State’s Opioid-Related Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reaches Agreement With Rhode Island to Settle Opioid-Related Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally
Palm Beach, FL –– February 24, 2022 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept... 
Via FinancialNewsMedia
Exposures COVID-19
Teva Reports Fourth Quarter and Full Year 2021 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reaches Agreement With Texas to Settle the State’s Opioid-Related Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
Research Finds COVID Pandemic Worsened Health Equity Gap
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results and 2022 Financial Guidance at 8 a.m. ET on February 9, 2022
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Statement Following New York Jury Ruling in Opioids Trial
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Launch of First-to-Market Generic Version of Narcan® (Naloxone Hydrochloride Nasal Spray), in the U.S.
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Launch of an Authorized Generic of Epiduo® Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the U.S.
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum Tender Amount and Election of Early Settlement
From Teva Pharmaceutical Industries Limited
Via Business Wire
The $11 Trillion Healthcare Industry Is About To Change Forever
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 4, 2021 – The $11-trillion healthcare industry is going fully digital, disrupting industry giants & government... 
Via FinancialNewsMedia
Teva Becomes First Pharmaceutical Company to Execute Sustainability-linked Bond Tied to both Climate and Access to Medicine Targets
From Teva Pharmaceutical Industries Ltd.
Via Business Wire
Teva Announces Successful Upsize of Sustainability-Linked Senior Notes Offering and Pricing of $5,000,000,000 of Sustainability-Linked Senior Notes
From Teva Pharmaceutical Industries Limited
Via Business Wire
California Judge Rules That Teva Did Not Cause a Public Nuisance or Make False or Misleading Statements About Opioids
From Teva Pharmaceutical Industries Limited
Via Business Wire
New Phase 3 Data Presented at Psych Congress 2021 Showed TV-46000/mdc-IRM Significantly Prolonged Time to Impending Relapse Compared to Placebo in Patients with Schizophrenia
From Teva Pharmaceutical Industries Limited
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.